Pulmonx Corporation (NASDAQ:LUNG) Q2 2021 Earnings Conference Call August 3, 2021 4:30 PM ET Company Participants Brian Johnston - IR, Gilmartin Group Glen French - President and CEO Derrick Sung - CFO Conference Call Participants Bob Hopkins - BofA Securities, Inc. Cecilia Furlong - Morgan Stanley Larry Biegelsen - Wells Fargo Securities Rick Wise - Stifel Financial Corp Bill Plovanic - Canaccord Genuity Jason Bednar - Piper Sandler Joanne Wuensch - Citi Operator Good afternoon. Thank you for standing by, ...

NASDAQ: LUNG August 2021 © 2021 Pulmonx Corporation1 Forward Looking Statement This presentation and certain statements made during this presentation contain forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business st ...

NASDAQ: LUNG May 2021 © 2021 Pulmonx Corporation1 Forward Looking Statement This presentation and certain statements made during this presentation contain forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

Pulmonx Corporation (NASDAQ:LUNG) Q1 2021 Results Conference Call May 4, 2021 4:30 PM ET Company Participants Brian Johnston - IR, Gilmartin Group Glen French - President and CEO Derrick Sung - CFO Conference Call Participants Bob Hopkins - Bank of America Marissa Bych - Morgan Stanley Rick Wise - Stifel Joanne Wuensch - Citibank Jason Bednar - Piper Sandler Operator Good day, and thank you for standing by. Welcome to the Pulmonx Q1 2021 Earnings Conference Call. [Operator Instructions] I would now like to ...

Financial Performance - For the years ended December 31, 2020 and 2019, the company incurred net losses of $32.2 million and $20.7 million, respectively, with an accumulated deficit of $242.7 million as of December 31, 2020[256]. - The company expects to continue incurring net losses and negative cash flows from operations for the foreseeable future, necessitating additional capital[335]. - The company has incurred significant net losses since inception, with an accumulated deficit of $242.7 million as of December 31, 2020[333]. - As of December 31, 2020, the company had $231.6 million in cash and cash equivalents, which is expected to fund operations for at least the next twelve months[333]. Market and Product Dependency - The company relies solely on the Zephyr Valve, which is currently approved only for treating severe emphysema, limiting its market potential[261]. - Sales of Zephyr Valves and delivery catheters accounted for most of the company's revenue for the years ended December 31, 2020 and 2019, and are expected to continue to do so[262]. - The company derives substantially all revenue from product sales to hospitals and distributors, with positive coverage policies from commercial payors like Aetna and Humana as of December 31, 2020[283]. - International sales accounted for approximately 50.5% of revenue in 2020, down from 67.2% in 2019, indicating a shift in market focus[344]. Regulatory and Compliance Challenges - The company must obtain and maintain necessary regulatory approvals for its products, such as the Zephyr Valve, to avoid negative impacts on its financial condition[369]. - The FDA's approval processes for medical devices can be lengthy and unpredictable, potentially delaying product launches[372]. - The company is subject to FDA regulations requiring reporting of any incidents that may cause serious injury or death, which could lead to recalls or enforcement actions[390]. - The company must ensure compliance with the FDA's Quality System Regulation and the European Union Medical Devices Directive to avoid disruptions in manufacturing and distribution[404]. Operational Risks - The company relies on a limited number of single-source suppliers for critical components, making it vulnerable to supply shortages and price fluctuations[299]. - Manufacturing capabilities are limited, and the company does not have redundant facilities, which could impact operations if any facility suffers damage[302]. - The company faces risks in accurately forecasting customer demand, which could lead to inventory write-downs or reputational damage if demand is underestimated[304]. - The company is dependent on its information technology systems for efficient operations, and disruptions could negatively impact its business[315]. Competition and Market Dynamics - The company faces competition from larger firms with established products and resources, which may hinder market penetration[329]. - Increased competition in international markets due to more products receiving regulatory approval could affect market position[345]. - Consolidation in the healthcare industry could lead to demands for price concessions, affecting product pricing strategies[356]. Sales and Marketing Strategy - The company anticipates ongoing significant sales and marketing, research and development, and regulatory expenses as it seeks to grow its sales force and expand marketing efforts[256]. - The company plans to continue expanding its sales and marketing infrastructure to increase the number of customers and emphysema centers of excellence, which requires significant time and expense[292]. - The company must maintain strong relationships with physicians for product development and marketing, as any failure could negatively impact business operations[295]. Legal and Liability Risks - The company faces risks related to product liability claims, which could result in substantial liabilities and reputational harm[317]. - Serious complications from the Zephyr Valve, including pneumothoraces and death, could limit adoption and lead to costly litigation, negatively impacting business operations[281]. - The company has incurred costs related to ongoing litigation, which could divert management's attention and resources[316]. Economic and Environmental Factors - The overall smoking rate in the U.S. has declined from 42.4% in 1965 to 13.7% in 2018, potentially reducing the number of patients suffering from COPD and emphysema[313]. - The company is subject to unfavorable global economic conditions that could weaken demand for its solutions and affect financial stability[353]. - Compliance with environmental laws may be expensive, and noncompliance could result in substantial fines and liabilities, negatively impacting financial condition[451]. Cybersecurity and Data Privacy - Cybersecurity threats are evolving, and the company is investing in protections to safeguard sensitive information, with potential risks to operations if breaches occur[348]. - The company is subject to diverse data privacy regulations, including the GDPR, with potential fines of up to €20 million or 4% of global annual revenue for significant breaches[440]. - The company cannot guarantee that third-party service providers will comply with privacy obligations, which could lead to data security breaches and negatively affect operations[444]. Clinical Trials and Research - The company has conducted clinical trials involving approximately 450 patients using the Chartis System, demonstrating safety and effectiveness, but long-term data on the Zephyr Valve is still limited[294]. - The LIBERATE extension study is required to follow up on safety and effectiveness for up to five years, with results expected in February 2023[294]. - The clinical trial process is lengthy and expensive, with uncertain outcomes, and the company may face significant setbacks during these trials[413][415]. Management and Personnel - The company has significant reliance on its senior management team, and the loss of key personnel could negatively impact business operations[340]. - The company trains its marketing and sales force to avoid promoting off-label uses of its products, but cannot prevent physicians from using them in such a manner[409][411].

Pulmonx Corporation (NASDAQ:LUNG) Q4 2020 Earnings Conference Call March 2, 2021 4:30 PM ET Company Participants Brian Johnston - Investor Relations Glendon French - President & Chief Executive Officer Derrick Sung - Chief Financial Officer Conference Call Participants Robert Hopkins - Bank of America Frederick Wise - Stifel Lawrence Biegelsen - Wells Fargo Securities William Plovanic - Canaccord Genuity Operator Good afternoon, and welcome to Pulmonx Fourth Quarter and Full Year 2020 Earnings Conference Ca ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other ...